Participated · Series B · Dec 2021

AnHeart Therapeutics is a clinical-stage global biopharmaceutical group developing next-generation precision oncology therapeutics, operating from offices in the US and China and registered in the Cayman Islands as AnBio Therapeutics Ltd. Its lead asset, taletrectinib, is a potent, highly selective next-generation ROS1/NTRK inhibitor in Phase 2 trials for first- and second-line ROS1 fusion–positive NSCLC and in an NTRK fusion–positive solid tumor basket trial; it is reported to cross the blood–brain barrier and overcome crizotinib resistance. Taletrectinib is being studied in the China TRUST trial (NCT04395677), the global TRUST II trial (NCT04919811), and the NTRK basket trial (NCT04617054), and interim TRUST Phase 2 data for NSCLC have been published at ASCO and CSCO. The company’s pipeline also includes AB-218, an mIDH1 inhibitor in Phase 2 for lower grade glioma, cholangiocarcinoma, AML and other tumors, and AB-329, an AXL inhibitor in Phase 1 intended for use in combination with checkpoint inhibitors or chemotherapies. The company plans to use recent proceeds to advance taletrectinib’s clinical development and to support continued expansion of its precision oncology pipeline and team. Since its founding in December 2018, AnHeart has raised $100 million in gross proceeds from private financings. AnHeart Therapeutics is a clinical-stage biopharmaceutical company focused on developing oncology therapies, headquartered in Hangzhou with offices in Beijing, Shanghai and New York. Its lead candidate, taletrectinib, is a next-generation, potent and highly selective ROS1/NTRK inhibitor that can cross the blood–brain barrier and was licensed from Daiichi Sankyo. Two Phase 1 studies in the U.S. and Japan reported promising safety and efficacy, with mPFS of 24.9 months in TKI‑naïve patients and 18.4 months in 1 TKI‑pretreated patients (data cutoff March 2019). Taletrectinib inhibits both ROS1 fusion wild type and crizotinib-resistant secondary mutations, including G2032R, and is being advanced into global Phase 2 trials. The company plans to use proceeds from its recent financing to execute the global development plan for taletrectinib and to expand and deepen its oncology portfolio over time. AnHeart was formed in November 2018 and is managed by industry veterans and financially backed by venture capital funds.